**11.1. Treatment of nondestructive lesions**

Reduction of immunosuppression is typically recommended for patients with early lesions. If there is residual disease or reduction in immunosuppression is not tolerated or allowable due to concerns regarding the donor graft, rituximab may be utilized.

**References**

2004;**77**(1):76-84

976-983

2010;**15**(3):80-86

**26**(6):677-683

733-742

[1] Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: Classifi-

Clinical and Pathological Review of Post Transplant Lymphoproliferative Disorders

http://dx.doi.org/10.5772/intechopen.75356

405

[2] Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, Rabian C, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: Relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation.

[3] Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2011;**17**(6):901-907

[4] Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders

[5] Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU. Associations between EBV serostatus and organ transplant type in PTLD risk: An analysis of the SRTR National Registry Data in the United States. American Journal of Transplantation. 2012;**12**(4):

[6] Dharnidharka VR, Martz KL, Stablein DM, Benfield MR. Improved survival with recent post-transplant Lymphoproliferative disorder (PTLD) in children with kidney trans-

[7] Manez R, Breinig MK, Linden P, Kusne S, Torre-Cisneros J, Wilson J, et al. Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transplant

[8] Khedmat H, Characteristics TS. Prognosis of post-transplant lymphoproliferative disorders within renal allograft: Report from the PTLD.Int. survey. Annals of Transplantation.

[9] Rasche L, Kapp M, Einsele H, Mielke S. EBV-induced post transplant lymphoproliferative disorders: A persisting challenge in allogeneic hematopoetic SCT. Bone Marrow

[10] Sanz J, Andreu R. Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation. Current Opinion in Oncology. 2014;

[11] Orjuela MA, Alobeid B, Liu X, Siebert AL, Kott ER, Addonizio LJ, et al. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. British Journal of Haematology. 2011;**152**(6):

(PTLD) in the rituximab era. Leukemia & Lymphoma. 2005;**46**(2):191-196

plants. American Journal of Transplantation. 2011;**11**(4):751-758

International. 1994;**7**(Suppl 1):S235-S237

Transplantation. 2014;**49**(2):163-167

cation and treatment. The Oncologist. 2008;**13**(5):577-585
